Open Access

Longitudinal diffusion tensor imaging in amyotrophic lateral sclerosis

  • Carsten Keil3,
  • Tino Prell1Email author,
  • Thomas Peschel2,
  • Viktor Hartung1,
  • Reinhard Dengler3 and
  • Julian Grosskreutz1
Contributed equally
BMC Neuroscience201213:141

DOI: 10.1186/1471-2202-13-141

Received: 12 May 2012

Accepted: 31 October 2012

Published: 8 November 2012

Abstract

Background

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder, caused by progressive loss of motor neurons. Changes are widespread in the subcortical white matter in ALS. Diffusion tensor imaging (DTI) detects pathological changes in white matter fibres in vivo, based on alterations in the degree (diffusivity, ADC) and directedness (fractional anisotropy, FA) of proton movement.

Methods

24 patients with ALS and 24 age-matched controls received 1.5T DTI. FA and ADC were analyzed using statistical parametric mapping. In 15 of the 24 ALS patients, a second DTI was obtained after 6 months.

Results

Decreased FA in the corticospinal tract (CST) and frontal areas confirm existing results. With a direct comparison of baseline and follow-up dataset, the progression of upper motor neuron degeneration, reflected in FA decrease, could be captured along the CST and in frontal areas. The involvement of cerebellum in the pathology of ALS, as suspected from functional MRI studies, could be confirmed by a reduced FA (culmen, declive). These structural changes correlated well with disease duration, ALSFRS-R, and physical and executive functions.

Conclusion

DTI detects changes that are regarded as prominent features of ALS and thus, shows promise in its function as a biomarker. Using the technique herein, we could demonstrate DTI changes at follow-up which correlated well with clinical progression.

Keywords

Cerebellum Amyotrophic lateral sclerosis Diffusion tensor imaging Follow-up

Background

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder characterized by progressive failure of upper and lower motor neurons. In the ALS brain, degeneration of fibres is widespread in the subcortical white matter with surrounding astrogliosis. Degeneration commonly extends into the corticospinal tract (CST), the central part of the corpus callosum and in frontal areas as well as in long projection fibres as seen in post-mortem tissue [1, 2]. Previous studies have demonstrated white matter changes in ALS using diffusion tensor imaging (DTI), a technique that detects alterations in both degree (diffusivity, ADC) and directedness (fractional anisotropy, FA) of proton movement reflecting changes in microstructural tissue and fibre organisation [3]. In ALS, DTI revealed a variable, but widespread pattern of white matter abnormalities which were most prominent along the CST and the subcentral white matter, and which extended into frontal regions [49].

Symptoms indicating involvment of lower motor neurons such as atrophic paresis may sometimes obscure signs of upper motor neuron failure leading to a delay in diagnosis and treatmentof ALS. Therefore, a biomarker for diagnostic, prognostic, and monitoring purposes is needed. Here, DTI shows promise as a potential biomarker, however, longitudinal studies are required to further clarify the time course and distribution of changesdetected by this technique. By customizing scripting in the Statistical Parametric Mapping software (SPM, http://www.fil.ion.ucl.ac.uk/spm) we aimed to analyze DTI datasets from 24 ALS patients, without having to make a priori assumptions about localization of pathology. To obtain longitudinal data on progress of microstructural changes in ALS, a second examination was undertaken in a subset of 15 patients at 6 months.

Methods

Subjects

We studied DTI image sets of 24 patients (T0) with sporadic ALS and of 24 healthy age-matched controls. In a subset of 15 of the 24 ALS patients (Follow-up), a second examination was performed 6 months later. In the 24 ALS patients, the mean (± S.D.) duration since onset of dysarthria or weakness (termed disease duration) at MRI was 25.6 (± 27,8) months, the mean age was 62.4 ± 10.5 (range 32.7–75.9) years, and the mean revised ALS functional rating scale (ALSFRS-R) was 36.3 ±9 points. The female to male ratio was 1:1. 9 patients had a bulbar onset and 15 patients had, limb onset of weakness. All patients were being treated with riluzole and none were taking psychoactive drugs. Significant frontal or cognitive dysfunctions were ruled out by means of the Mini Mental State Examination (MMSE) and the Frontal Assessment Battery test (FAB). In addition, the 36-item Short Form Health Survey (SF36) was completed by all patients enrolled and the physical and executive subset was used for correlation analysis. The 24 age-matched healthy controls (mean age 61.6 ± 9.2, range 36.6 – 71.9) had no history of a disease of the central nervous system, their neurological examinations were normal, and MRI T1 and T2 images revealed no pathological findings. Finally, clinical diagnosis of ALS was made according to the revised El-Escorial criteria. Disease characteristics of patients enrolled in the study are summarized in Table 1[10]. All subjects gave written informed consent to participate in the study, which was approved by the local ethics committee.
Table 1

Characteristics of ALS patients

#

Age

Sex

Onset

El escorial

Disease duration mth

MMST

FAB

ALSFRS-R

SF36 physic

0

6

0

6

0

6

0

6

1*

67.9

f

b

p

3

30

 

17

 

45

45

100

100

2

72.5

f

b

p

6

30

30

17

18

44

 

100

 

3*

58.1

f

b

p

4

29

28

16

18

46

43

25

20

4*

72.0

m

l

p

31

30

29

17

17

39

32

35

35

5

75,9

m

l

p

15

29

 

12

 

25

 

5

 

6*

64,8

m

l

d

33

29

28

15

12

32

27

0

0

7

64,4

m

l

p

32

30

 

16

 

43

 

20

 

8*

32,7

m

l

d

19

30

30

18

18

30

27

0

0

9*

44,3

f

l

d

32

29

no

18

no

18

18

0

0

10*

64,5

f

l

s

3

28

27

15

9

45

35

10

5

11*

69,3

m

b

d

16

30

29

14

16

33

32

0

0

12*

70

f

l

s

37

27

30

15

18

35

31

10

10

13

68,6

f

b

p

7

21

 

12

 

47

 

100

 

14*

67,5

m

l

p

22

29

28

18

18

45

45

95

95

15*

49,7

m

l

s

10

30

 

17

 

47

 

60

0

16*

64,8

f

l

d

52

30

30

18

18

37

37

0

0

17

48,3

f

l

d

104

no

no

no

no

21

21

0

 

18*

71,3

m

b

p

8

27

 

15

 

40

 

35

15

19

60,2

m

l

p

18

29

30

15

18

39

39

25

 

20

54,9

d

l

p

13

29

 

18

 

27

 

0

 

21*

55,1

m

b

p

2

29

 

16

 

45

 

85

0

22*

64,1

f

b

d

13

30

30

15

15

34

25

45

30

23

74,4

m

l

p

107

30

30

17

17

32

32

30

 

24*

65,3

f

b

p

28

29

 

18

 

21

 

0

15

MW

61,5

   

25,6

28,9

29,2

16,0

16,3

36,3

32,6

32,5

20,3

SD

10,9

   

27,8

1,9

1,1

1,8

2,8

9,0

8,3

37,2

32,2

S.D. standard deviation, f/m female/male ratio, s suspected, p probable, d definite, l limb onset, b bulbar onset, T0 (month 0), 6 follow-up (month 6), * patients, who underwent follow-up.

Data acquisition

Images were acquired on a neuro-optimized 1.5-T GE Signa Horizon LX (General Electric Company, Milwaukee, WI, USA) using a 3-dimensional T1-weighted spoiled gradient recalled echo (SPGR) sequence generating 124 contiguous sagittal slices (RT 24ms; TE 8ms; flip angle 30°, 2 averages, acquisition time 13'10", in plane resolution 0.97 × 0.97 × 1.5 mm [3]). DTI was performed using echoplanar imaging (EPI) (39 contiguous slices, 3 mm thickness, 2 × 2 mm in plane resolution, 24 directions, b=1000, total scanning time 25 min). During scanning, all participants were placed comfortably and their heads were fixated within the headcoil using special cushions. All subjects received additional T2-weighted images to exclude cerebrovascular disease.

Pre-processing

Data were processed on a standard IBM-compatible PC using SPM2 statistical parametric mapping software (Welcome Department of Cognitive Neurology, London) in the analysis environment MATLAB (version 6.1; the Math Works Inc, Natick, Mass). Images were reoriented into oblique axial slices aligned parallel to the anterior-posterior commissural axis with the origin set to the anterior commissure.

After calculatingthe FA and ADC maps, images were pre-processed and analyzed by statistical parametric mapping (SPM2) using an approach adopted from voxel-based morphometry as described herein by our group [11]. This included an optimized normalisation procedure, together with an automated exclusion of skull and CSF signal values and smoothing (6-mm FWHM). All EPI scans were normalized to the EPI-template provided by SPM and further used to create a site-specific EPI template appropriate to the population sample and with scanner specific image contrast. This site-specifc template was used again for normalisation and brain extraction for the individual images in the group studied, which resulted in optimal normalization and cleaning parameters for use with the FA and ADC images.

Statistical analysis

Processed images of each tissue class were analyzed in the framework of the general linear model. ANCOVA was applied to compare the groups of patients and healthy controls (p < 0.05, corrected for the entire volume). Additionally, regression analyses with clinical measures were explored for ALS patients using the SPM2 model 'single subjects: covariates only'. In accordance with our anatomical a priori hypothesis regarding white matter changes in ALS along the CST, the statistical threshold was set at p < 0.001, corrected. For regions where changes could be expected in the follow-up (CST) [11, 12], a small volume correction (SVC) was undertaken and the family-wise-error (FWE)-method (P < 0,05) for multiple comparisons was used.

Results

Clinical characterization

A total of 24 patients with sporadic ALS and the same number of age- and gender-matched healthy controls underwent MRI (T0) . In addition, DTI was performed in 15 patients with ALS after six months (follow-up). Based on MMST and FAB, no significant cognitive or executive impairment was observed in the T0 (MMST 28.8 ± 1.57, FAB 16.04 ± 1.80) and in the follow-up group (MMST 29.2 ± 1.07, FAB 16.31 ± 2.81). Three patients switched from possible to probable laboratory-supported ALS according to the revised El Escorial criteria. In the follow-up group, theALSFRS-R and the physical functioning SF36 subscore decreased from 35.4 (± 8.4) to 32,6 (± 8.3) and from 25,0 (± 33,0) to 20,7 (± 33,3) points, respectively after 6 months. Both reductions were not significant. Clinical characteristics of patients are summarized in Table 1.

Whole-brain group differences in FA and ADC at T0

In the motor system, the FA in the ALS patient group (n=24) was reduced within the precentral gyrus, in the supplementary motor cortex, as well as in the CST at the level of corona radiata, pons, and crus cerebri compared to healthy controls. Further, FA was reduced in the corpus callosum, the parahippocampal gyrus and in frontal areas (Table 2).
Table 2

Results of group comparisons of ALS patients versus controls

 

Side

Cluster size

x

y

z

T

p

T0 FA all ALS patients (n=24) < controls

       

Corpus Callosum

l

7954

-10

-14

29

6.03

0.002

Corpus Callosum

l

 

-1

-16

25

5.35

0.003

Corpus Callosum

r

 

11

-16

29

5.29

0.003

Brainstem, Pons, CST

l

1589

-8

-27

-34

5.82

0.002

Brainstem, Pons, CST

r

 

9

-26

-36

4.54

0.007

Brainstem, Pons, CST

r

 

10

-22

-24

3.88

0.027

Precentral Gyrus, WM

r

2386

14

-21

58

5.69

0.002

subgyral, WM, Corona Radiata

r

 

27

-38

50

4.02

0.021

Medial Frontal Gyrus, WM, below BA 6

l

743

-12

-13

70

5.03

0.003

Precentral Gyrus, WM

r

290

48

4

8

4.59

0.007

Corona Radiata, Medial Frontal Gyrus, below BA 6

l

687

-35

-12

48

4.37

0.01

Precentral Gyrus, WM

l

 

-39

-19

48

4.18

0.015

subgyral, WM, below Gyrus postcentralis

l

201

-10

-37

61

4.35

0.011

Precentral Gyrus, subgyral, WM, Corona Radiata

l

343

-42

-15

23

4.34

0.011

Precentral Gyrus, WM

l

942

-28

-24

55

4.26

0.013

Frontal Lobe, subgyral, WM, Corona radiata

l

 

-17

-24

55

3.62

0.042

Frontal Lobe, subgyral, WM, Corona radiata

r

345

33

-8

38

3.87

0.028

Frontal Lobe, Precentral Gyrus, WM, Corona radiata

l

309

-39

-6

35

3.86

0.028

Frontal Lobe, Precentral Gyrus, BA 6

l

 

-46

1

40

3.82

0.03

Limbic Lobe, Parahippocampal Gyrus, WM

l

218

-20

-48

-11

3.80

0.032

T0 ADC all ALS patients (n =24) > controls

       

Precentral Gyrus, WM

l

5108

-9

-25

67

5.99

0.02

Precentral Gyrus, subgyral, WM, below BA 6

l

 

-28

-16

65

5.5

0.02

Frontal Lobe, subgyral, WM, Corona radiata

l

 

-28

-25

50

5.33

0.02

Precentral Gyrus, subgyral, WM

r

5537

21

-16

65

5.56

0.02

Precentral Gyrus, WM

r

 

11

-23

67

5.22

0.02

Frontal Lobe, subgyral, WM, Postcentral Gyrus

r

 

15

-34

61

4.31

0.031

Brainstem, Pons

r

3243

6

-22

-28

5.13

0.02

Brainstem, Pons

l

 

-4

-23

-28

4.21

0.034

Limbic Lobe, Parahippocampal Gyrus, WM

r

 

26

-14

-14

3.98

0.041

Temporal Lobe, Superior Temporal Gyrus, GM

l

547

-62

-12

-1

4.90

0.02

Parietal Lobe, Superior Parietal Lobule, subgyral, BA 7

r

754

21

-50

65

4.73

0.022

Precentral Gyrus, WM

r

336

47

-2

31

4.55

0.025

Postcentral Gyrus, subgyral, WM

l

645

-18

-32

71

4.22

0.034

Postcentral Gyrus, subgyral, WM

l

 

-27

-31

67

4.02

0.04

Frontal Lobe, Superior Frontal Gyrus, GM, BA 9

l

467

-22

42

39

4.15

0.036

Frontal Lobe, subgyral, WM

l

 

-25

39

29

3.78

0.046

Temporal Lobe, subgyral, WM

l

409

-32

9

-35

4.11

0.037

Frontal Lobe, Superior Frontal Gyrus, WM

r

269

5

20

53

4.02

0.04

Frontal Lobe, Medial Frontal Gyrus, GM, BA 8

l

383

-6

27

53

4.02

0.04

Limbic Lobe, Uncus, WM

r

827

22

-3

-36

3.95

0.041

Limbic Lobe

r

 

22

-8

-43

3.68

0.049

Frontal Lobe, Precentral Gyrus, subgyral, WM

l

231

-51

-3

23

3.91

0.042

Sub-lobar, Insula, WM

l

208

-40

-17

19

3.89

0.043

Frontal Lobe, Superior Frontal Gyrus, GM

l

233

-22

10

57

3.88

0.043

Frontal Lobe, Middle Frontal Gyrus, GM, BA 8

l

217

-23

20

50

3.87

0.043

Frontal Lobe, Middle Frontal Gyrus, GM, BA 10

r

365

27

53

26

3.81

0.045

Frontal Lobe, Superior Frontal Gyrus, GM, BA 9

r

 

24

45

39

3.71

0.048

Follow-up FA all ALS patients (n =15) < controls

       

Precentral Gyrus, subgyral, WM, Corona radiata

r

293

48

4

6

6.26

0.017

Corpus Callosum

l

3260

-8

-18

28

5.70

0.017

Corpus Callosum

r

 

11

-17

28

4.8

0.026

Left Brainstem, Pons

l

218

-6

-28

-38

5.02

0.02

Limbic Lobe, Parahippocampal Gyrus, WM

l

1004

-22

-42

-10

4.89

0.023

Temporal Lobe, Fusiform Gyrus, GM, BA 37

l

 

-27

-37

-16

4.26

0.04

Sub-lobar, Thalamus, GM, Pulvinar

l

217

-13

-33

1

4.51

0.033

Frontal Lobe, Medial Frontal Gyrus, WM, Corona radiata

r

696

13

-26

58

4.44

0.035

Frontal Lobe, Medial Frontal Gyrus, WM, Corona radiata

r

 

9

-27

69

4.28

0.04

parahippocampal Amygdala

r

206

29

-30

-26

4.36

0.037

Limbic Lobe, Parahippocampal Gyrus, GM, BA 34

r

204

17

-7

-19

4.20

0.043

Follow-up ADC all ALS patients (n =15) > controls

       

Precentral Gyrus, WM

r

3258

24

-20

63

6.18

0.036

Precentral Gyrus, subgyral, WM

r

 

12

-21

62

5.01

0.001*

Precentral Gyrus, subgyral, WM, Corona radiata

r

 

18

-20

43

4.1

0.013*

Sub-lobar, Extra-Nuclear, WM, Internal capsule, Crus post.

r

379

18

-13

-1

4.32

0.008*

Sub-lobar, Extra-Nuclear, WM, Internal capsule, Crus post.

l

1234

-18

-13

-2

4.28

0.009*

Sub-lobar, Extra-Nuclear, WM, Internal capsule, Crus post.

l

 

-19

-12

6

4.13

0.012*

Precentral Gyrus, WM

l

351

-9

-25

65

4.27

0.009*

Precentral Gyrus, subgyral, WM, Corona radiata

l

1148

-37

-11

43

4.16

0.011*

Precentral Gyrus, subgyral, WM, Corona radiata

l

 

-28

-25

50

4.16

0.012*

Precentral Gyrus, subgyral, WM, Corona radiata

l

 

-25

-22

42

4.06

0.012*

subgyral, WM, Corona radiata, below BA 6

l

241

-13

-14

59

4.08

0.014*

Ordered by descending T-values. R=right; L=left, * SVC 10mm (FWE).

Diffusivity was enhanced in the motor system (precentral gyrus, premotor area, CST at the level of corona radiate, pons), the postcentral gyrus, and in frontal and temporal areas (Table 2). Enhanced diffusivity in the pons was rostrally located to pontine FA decrease.

Whole-brain group differences in FA and ADC at follow-up

According to T0 MRI in ALS patients (n=15) after 6 months, the FA was reduced in the CST (corona radiate), the pons, the corpus callosum, and the parahippocampal gyrus. Additionally , FA was found decreased in frontal areas (gyrus frontalis medialis), insula, in the limbic system (amygdale), and in the thalamus at this time point (Table 2, Figure 1).
https://static-content.springer.com/image/art%3A10.1186%2F1471-2202-13-141/MediaObjects/12868_2012_Article_2819_Fig1_HTML.jpg
Figure 1

Group comparisons of ALS patients versus controls. A results are superimposed on the mean of all subjects of spatially normalized anisotropy images. Voxels with a significant decrease in FA in the patients versus controls are found in the precentral gyrus, the CST and pons (p < 0,001 uncorrected). ADC results are superimposed on the mean of all subjects of spatially normalized anisotropy images. Voxels with a significant increase in ADC in the patients versus controls are found in the precentral gyrus, CST, pons, frontal ares and limbic system (p < 0,001 uncorrected).

In the follow-up group, the diffusivity was again enhanced in the motor system (right precentral gyrus, and in the CST at the level of corona radiate, internal capsula). After SVC, there was a decrease in FA bilaterally in the WM of precentral gyrus, along the CST (corona radiate), and in the limbic system (fusiform gyrus, uncus) (Table 2, Figure 1). After 6 months, microstructural changes had progressed along the descending fibres and into the internal capsule.

Comparison of T0 to follow-up

Results of the 15 ALS patients, who had undergone follow-up DTI analysis were compared to their T0 data by means of the paired t-test. FA was significantly reduced at follow-up in the precentral gyrus, CST (at the mesencephal level), in the cerebellum (culmen, declive), the temporal and parietal lobe. Diffusivity was significantly enhanced after 6 months both in the internal and external capsule (Table 3, Figure 2).
Table 3

Results of direct comparisons of ALS patients and correlation analysis

 

Side

Cluster size

x

y

z

T

p

Paired t-test FA T0 / Follow-up

       

Temporal Lobe, Superior Temporal Gyrus, GM, BA 39

l

879

-49

-62

28

7.5

0.001*

Temporal Lobe, Superior Temporal Gyrus, GM, BA 39

l

 

-56

-64

16

4.82

0.033*

Parietal Lobe, Supramarginal Gyrus, GM, BA 40

l

 

-58

-61

30

4.19

0.075*

Cerebellum, Posterior Lobe, Declive

r

921

24

-59

-25

6.88

0.002*

Cerebellum, Anterior Lobe, Culmen

r

 

34

-52

-21

4.25

0.07*

Precentral Gyrus, WM

r

743

44

-9

41

6.67

0.003*

Precentral Gyrus, WM

r

 

53

-6

43

5.56

0.012*

Superior Temporal Gyrus, WM

r

2014

65

-39

10

6.36

0.004*

Superior Temporal Gyrus, GM, BA 22

r

 

61

-59

16

5.95

0.008*

Superior Temporal Gyrus, GM, BA 22

r

 

65

-48

20

5.12

0.022*

Parietal Lobe, Precuneus, WM

r

582

35

-74

39

6.21

0.005*

Brainstem, Midbrain, CST

r

270

16

-16

-17

5.89

0.008*

Temporal Lobe

r

756

44

8

-42

5.72

0.01*

Superior Frontal Gyrus, WM

r

221

35

39

35

5.27

0.018*

Middle Frontal Gyrus, subgyral, WM

r

 

29

34

31

4.76

0.035*

Superior Frontal Gyrus, GM, BA 11

r

487

28

45

-18

4.90

0.03*

Temporal Lobe, Middle Temporal Gyrus, WM

r

253

60

-7

-9

4.77

0.035*

Temporal Lobe, Superior Temporal Gyrus, WM

r

 

57

-2

3

4.33

0.063*

Paired t-test ADC T0 / Follow-up

       

Extra-Nuclear, WM, External capsule

l

2054

-28

2

-3

6.38

0.003*

Extra-Nuclear, WM, External capsule

l

 

-29

-15

11

6.16

0.004*

Extra-Nuclear, WM, External capsule

l

 

-25

-1

8

5.5

0.01*

Extra-Nuclear, WM, Internal capsule

l

383

-19

8

3

5.94

0.005*

Ordered by descending T-values. R=right; L=left, * SVC 10mm (FWE).

https://static-content.springer.com/image/art%3A10.1186%2F1471-2202-13-141/MediaObjects/12868_2012_Article_2819_Fig2_HTML.jpg
Figure 2

Direct comparison between T0 and follow-up in ALS patients. Comparison of FA results between T0 and follow-up (n=15) with paired t-test superimposed on the mean of all subjects of spatially normalized anisotropy images. FA is significantly reduced in the follow-up in the precentral gyrus, CST (at the mesencephal level), in the cerebellum (culmen, declive), the temporal and parietal lobe (p < 0,001 uncorrected). Comparison of ADC results between T0 and follow-up (n=15) with paired t-test superimposed on the mean of all subjects of spatially normalized anisotropy images. Diffusivity is significantly enhanced after 6 months in the internal and external capsule (p < 0,001 uncorrected).

Correlation with clinical scores at T0

Disease duration negatively correlated with FA in precentral gyrus, CST (corona radiate, internal capsule) and the cerebellum, which means that in these areas FA decreases with time course of ALS. Changes in diffusivity did not correlate with disease duration. The ALSFRS-R positively correlated with FA in the CST, and the cerebellum. The ALSFRS-R did not correlate with diffusivity. Physical and executive function, reflected in SF36 subscore, positively correlated with FA in the cerebellum, but did not correlate with changes in diffusivity. This means that worsening ALS, indicated by a decrease of ALSFRS-R or SF36 subscore, is reflected as FA decrease in the CST and cerebellum (Table 4).
Table 4

Correlations with clinical data

 

Side

Cluster size

x

y

z

T

p

T0 FA correlation with ALSFRS-R

       

Right Brainstem, Midbrain

r

233

10

-24

-21

4.41

0.019*

Cerebellum, Posterior Lobe, Declive

r

251

13

-58

-19

3.99

0.04*

T0 FA correlation with disease duration

       

Precentral Gyrus, WM, below BA 6

r

596

4

-27

70

4.93

0.007*

Precentral Gyrus, subgyral, WM, Corona radiata

r

 

6

-30

61

4.52

0.014*

Sub-lobar, WM, CST, Internal capsule

l

867

-31

-26

17

4.58

0.013*

Sub-lobar, WM, CST, Internal capsule

l

 

-30

-18

15

4.47

0.017*

Cerebellum, Anterior Lobe, Culmen

r

317

12

-56

-15

4.56

0.014*

Sub-lobar, WM, CST, Corona radiata

l

202

-13

-29

51

4.37

0.02*

T0 FA correlation with SF36

       

Cerebellum, Anterior Lobe, Culmen

r

715

19

-43

-27

5.24

0.004*

Cerebellum, Anterior Lobe

r

 

10

-42

-33

4.4

0.019*

Cerebellum, Anterior Lobe

l

561

-10

-41

-33

4.84

0.008*

Cerebellum, Anterior Lobe, Culmen

l

 

-16

-42

-27

4.22

0.027*

Follow-up FA correlation with ALSFRS-R

       

Precentral Gyrus, subgyral, WM, BA 6

r

469

50

2

38

6.35

0.006*

Precentral Gyrus, subgyral, WM, BA 6

r

 

46

-5

46

6.11

0.008*

Frontal Lobe, Middle Frontal Gyrus, WM

r

233

33

13

50

5.99

0.01*

Precentral Gyrus, WM, Corona radiata

r

417

29

-15

56

5.87

0.011*

Precentral Gyrus, WM, Corona radiata

l

219

-16

-12

59

5.01

0.014*

Follow-up FA correlation with disease duration

       

Capsula Inerna, Crus post., CST

l

1722

-24

-19

2

6.87

0.003*

Sub-lobar, WM, Capsula Inerna, Crus post., CST

l

 

-28

-25

14

5.7

 

Internal capsule, Crus post., CST

r

408

24

-16

-4

5.69

0.014*

Internal capsule, Crus post., CST

r

 

32

-17

-5

4.12

 

External capsule

r

431

31

-12

10

5.61

0.015*

Follow-up FA correlation with SF36

       

Brainstem, Pons, CST

l

387

-11

-32

-34

5.37

0.02*

Ordered by descending T-values. R=right; L=left, * SVC 10mm (FWE).

Correlation with clinical scores at follow-up

After 6 months, the DTI data were correlated with clinical parameters. With respect to SVC, the FA negatively correlated with disease duration along the CST in the internal and external capsule. However, the decrease of FA was higher on the left side. Again diffusivity changes did not correlate with disease duration. ALSFRS-R positively correlated with FA in the precentral gyrus, the CST (corona radiate), the WM of right middle frontal gyrus and supplementary motor cortex. ALSFRS-R did not correlate with diffusivity changes. Physical and executive function (SF36 subscore) positively correlated with FA in the CST at brain stem level and negatively with diffusivity in the cerebellum (anterior lobe, dentatus, fastigium) and parahippocampal gyrus (Table 4).

Discussion

Involvement of the white matter in ALS is increasingly being recognized and extensive white matter abnormalities can be found in the region of the central sulcus and the CST, extending across the corpus callosum and into the frontal lobes [1]. The intact axonal membrane and the myelin coating of axons are important determinants for anisotropic diffusion in neural tissues [13] and therefore, a reduced FA along the CST in ALS patients reflects axonal fibre degeneration and myelin pallor [1].

In the present study, microstructural changes in the brains of ALS patients could be demonstrated as decreased FA and increased diffusivity mainly in the pyramidal motor system, frontotemporal areas, limbic system, and the cerebellum. Comparison of the follow-up group with healthy probands revealed a progressive decrease in FA and diffusivity increase along the CST after 6 months. Increasing fiber tract pathology during disease course could be verified by direct comparison of T0 with the follow-up DTI data from 15 patients. Brain structure pathology correlated well with disease duration, ALSFRS-R andthe SF-36 subscore for physical and executive function, predominantly in the range of motor system, but interestingly also in the cerebellum and the limbic system.

Widespread DTI changes in motoric and extramotoric systems in ALS

The decreased FA in the internal capsule and premotor cortex is in accordance with several DTI studies in ALS [4, 6, 8, 9, 1423]. Microstructural alterations in frontal areas are in line with bilateral frontal atrophy in VBM [11, 2426], an increase of diffusivity in frontal regions [21, 27] and observed in post mortem brain tissues [1]. Since the corpus callosum connects orbitofrontal and frontal cortices, its involvement in ALS is a consistent feature [9, 28] and together with the known DTI changes in the hippocampal formations, cingulum, and frontal white matter, may reflect cognitive impairment, which is often recognized in patients with ALS [29, 30]. However, aside from ruling out clinical significant dementia by means of MMSE and FAB, we did not undertake detailed neuropsychological testing.

Involvement of cerebellum in ALS

The cerebellum has been little studied in ALS, probably because of the lack of cerebellar signs in most patients. However, evidence for the involvement of cerebellum in ALS derives from early pathological [31, 32] and functional magnetic resonance imaging (fMRI) studies. Besides the enhanced activity in sensorimotor network, fMRI studies in ALS have demonstrated the recruitment of additional areas, such as the cerebellum and basal ganglia [3337]. Hence, it is probable that functional compensation in ALS relies on existing resources and mechanisms and not on development of new synapses or pathways [35]. Structural changes of cerebellum in ALS could be demonstrated as regional white matter alterations [26] and decreased grey matter volume [38] in VBM and as increased diffusivity in the anterior lobe of the cerebellum bilateral [21].

In the present study, the direct comparison after 6 months showed a reduced FA in the cerebellum (culmen, declive) of ALS patients. These structural changes correlated with disease duration, ALSFRS-R, physical and executive functions. Since, the cerebellum contributes to coordination and improvement of motor performance and is involved in motor learning [39], the abnormal connectivity found between the supplementary motor cortex and cerebellar areas is therefore not only of functional, but also of a structural nature [35, 37]. One could hypothesise that as a consequence of limited resources in the motor cortex, these cerebellar regions are activated due to an enhanced modulatory response in ALS. However, this compensation is paralleled by a progressive structural alteration of connectivity, finally leading to an ineffective modulation. However, the exact clinical and pathological relevance of these findings is not quite clear. We speculate that the structural changes in the cerebellum observed in the current study reflect a compensatory mechanism for the progressive loss of motor function. Further studies should evaluate cerebellar signs in more detail and undertake a comparison of cerebellar involvment in familal and sporadic ALS. Nevertheless with regard to studying cerebellar structures using DTI, several methodological limitations have to be taken into account such as the low resolution after normalization and the incomplete mapping of cerebellum. Moreover, measurement of radial and axial diffusivities would provide more specific information relating to diffusion tensor.

Follow-up

The few existing longitudinal DTI studies have captured the progression of upper motor neurone degeneration in ALS by demonstrating decreasing FA over time along the CST [4042]. Fibertracking of the mean CST showed a reduction of FA in a follow-up examination of ALS patients, indicating that degeneration of the CST appears to worsen over time [7]. In another six-month follow-up study, ALS patients showed DTI abnormalities that extended mainly into the bilateral frontal lobes [43]. Accordingly in our study, the disease progression was reflected in a progressive FA decrease along the CST, which correlated with disease duration and the decrease of ALSFRS-R. However, it is important to note that ALSFRS-R is a composite score of upper and lower motor neuron components, whereas FA changes along the CST may reflect more upon upper motor neuron degeneration. For further studies, it would be useful to correlate FA changes with ALSFRS-R subscores.

Furthermore, it remains unclear as to why regions with FA decrease (corona radiate, corpus callosum, brain stem) after 6 months appear smaller. In addition to method-based explanations, a possible interaction with swollen neighbouring motor neurones or astrocytes is also a plausible reason that could be discussed. Finally, we detected at 6 months follow-up that increase in diffusivity progressed in a caudal (CST) and frontal direction (premotor cortex). The direct comparison of follow-up patients with T0 data supports the observed progression of FA changes and revealed microstructural changes in regions which were not detected when comparing ALS patients with normal controls in the group comparison.

Conclusions

In summary, our study provides further evidence for the well known structural changes in the CST and in frontal areas in the brains of ALS. Further, we demonstrate the involvement of cerebellum as a feature of disturbed connectivity in ALS, supported by the correlation analysis with clinical datasets. It seems that the extent of ALS-related DTI abnormalities is greater than those identified by VBM analysis [9, 21], and that DTI can serve as stable biomarker in ALS [44].

Notes

Abbreviations

ADC: 

Apparent diffusion coefficient

ALS: 

Amyotrophic lateral sclerosis

CST: 

Corticospinal tract

DTI: 

Diffusion tensor imaging

FA: 

Fractional anisotropy.

Declarations

Acknowledgement

We thank Nasim Kroegel for proofreading.

Authors’ Affiliations

(1)
Department of Neurology, Jena University Hospital
(2)
Department of Psychiatry and Psychotherapy, Medical School Hannover
(3)
Department of Neurology and Clinical Neurophysiology, Medical School Hannover

References

  1. Smith MC: Nerve fibre degeneration in the brain in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 1960, 23: 269-282. 10.1136/jnnp.23.4.269.PubMed CentralPubMedView Article
  2. Rafalowska J, Dziewulska D: White matter injury in amyotrophic lateral sclerosis (ALS). Folia Neuropathol. 1996, 34: 87-91.PubMed
  3. Grosskreutz J, Peschel T, Unrath A, Dengler R, Ludolph AC, Kassubek J: Whole brain-based computerized neuroimaging in ALS and other motor neuron disorders. Amyotroph Lateral Scler. 2008, 9: 238-248. 10.1080/17482960802163622.PubMedView Article
  4. Sach M, Winkler G, Glauche V, Liepert J, Heimbach B, Koch MA, et al: Diffusion tensor MRI of early upper motor neuron involvement in amyotrophic lateral sclerosis. Brain. 2004, 127: 340-350. 10.1093/brain/awh041.PubMedView Article
  5. Abe O, Yamada H, Masutani Y, Aoki S, Kunimatsu A, Yamasue H, et al: Amyotrophic lateral sclerosis: diffusion tensor tractography and voxel-based analysis. NMR Biomed. 2004, 17: 411-416. 10.1002/nbm.907.PubMedView Article
  6. Agosta F, Pagani E, Rocca MA, Caputo D, Perini M, Salvi F, et al: Voxel-based morphometry study of brain volumetry and diffusivity in amyotrophic lateral sclerosis patients with mild disability. Hum Brain Mapp. 2007, 28: 1430-1438. 10.1002/hbm.20364.PubMedView Article
  7. Sage CA, Peeters RR, Gorner A, Robberecht W, Sunaert S: Quantitative diffusion tensor imaging in amyotrophic lateral sclerosis. Neuroimage. 2007, 34: 486-499. 10.1016/j.neuroimage.2006.09.025.PubMedView Article
  8. Muller HP, Lule D, Unrath A, Ludolph AC, Riecker A, Kassubek J: Complementary image analysis of diffusion tensor imaging and 3-dimensional t1-weighted imaging: white matter analysis in amyotrophic lateral sclerosis. J Neuroimaging. 2011, 21: 24-33. 10.1111/j.1552-6569.2009.00447.x.PubMedView Article
  9. Douaud G, Filippini N, Knight S, Talbot K, Turner MR: Integration of structural and functional magnetic resonance imaging in amyotrophic lateral sclerosis. Brain. 2011, 134 (Pt 12): 3470-3479.PubMedView Article
  10. Grosskreutz J, Kaufmann J, Fradrich J, Dengler R, Heinze HJ, Peschel T: Widespread sensorimotor and frontal cortical atrophy in Amyotrophic Lateral Sclerosis. BMC Neurol. 2006, 6: 17-10.1186/1471-2377-6-17.PubMed CentralPubMedView Article
  11. Grosskreutz J, Kaufmann J, Fraedrich J, Dengler R, Heinze HJ, Peschel T: Widespread sensorimotor and frontal cortical atrophy in Amyotrophic Lateral Sclerosis. BMC Neurol. 2006, 6: 17-10.1186/1471-2377-6-17.PubMed CentralPubMedView Article
  12. Turner MR, Cagnin A, Turkheimer FE, Miller CC, Shaw CE, Brooks DJ, et al: Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C](R)-PK11195 positron emission tomography study. Neurobiol Dis. 2004, 15: 601-609. 10.1016/j.nbd.2003.12.012.PubMedView Article
  13. Beaulieu C: The basis of anisotropic water diffusion in the nervous system - a technical review. NMR Biomed. 2002, 15: 435-455. 10.1002/nbm.782.PubMedView Article
  14. Ellis CM, Simmons A, Jones DK, Bland J, Dawson JM, Horsfield MA, et al: Diffusion tensor MRI assesses corticospinal tract damage in ALS. Neurology. 1999, 53: 1051-1058. 10.1212/WNL.53.5.1051.PubMedView Article
  15. Graham JM, Papadakis N, Evans J, Widjaja E, Romanowski CA, Paley MN, et al: Diffusion tensor imaging for the assessment of upper motor neuron integrity in ALS. Neurology. 2004, 63: 2111-2119. 10.1212/01.WNL.0000145766.03057.E7.PubMedView Article
  16. Iwata NK, Aoki S, Okabe S, Arai N, Terao Y, Kwak S, et al: Evaluation of corticospinal tracts in ALS with diffusion tensor MRI and brainstem stimulation. Neurology. 2008, 70: 528-532. 10.1212/01.wnl.0000299186.72374.19.PubMedView Article
  17. Yin H, Cheng SHT, Zhang J, Ma L, Gao Y, Li D, et al: Corticospinal tract degeneration in amyotrophic lateral sclerosis: a diffusion tensor imaging and fibre tractography study. Ann Acad Med Singapore. 2008, 37: 411-415.PubMed
  18. Lombardo F, Frijia F, Bongioanni P, Canapicchi R, Minichilli F, Bianchi F, et al: Diffusion tensor MRI and MR spectroscopy in long lasting upper motor neuron involvement in amyotrophic lateral sclerosis. Arch Ital Biol. 2009, 147: 69-82.PubMed
  19. Sage CA, Van Hecke W, Peeters R, Sijbers J, Robberecht W, Parizel P, et al: Quantitative diffusion tensor imaging in amyotrophic lateral sclerosis: revisited. Hum Brain Mapp. 2009, 30: 3657-3675. 10.1002/hbm.20794.PubMedView Article
  20. Senda J, Ito M, Watanabe H, Atsuta N, Kawai Y, Katsuno M, et al: Correlation between pyramidal tract degeneration and widespread white matter involvement in amyotrophic lateral sclerosis: A study with tractography and diffusion-tensor imaging. Amyotroph Lateral Scler. 2009, 10 (5-6): 288-294. 10.3109/17482960802651717.PubMedView Article
  21. Canu E, Agosta F, Riva N, Sala S, Prelle A, Caputo D, et al: The topography of brain microstructural damage in amyotrophic lateral sclerosis assessed using diffusion tensor MR imaging. AJNR Am J Neuroradiol. 2011, 32: 1307-1314. 10.3174/ajnr.A2469.PubMedView Article
  22. Iwata NK, Kwan JY, Danielian LE, Butman JA, Tovar-Moll F, Bayat E, et al: White matter alterations differ in primary lateral sclerosis and amyotrophic lateral sclerosis. Brain. 2011, 134: 2642-2655. 10.1093/brain/awr178.PubMed CentralPubMedView Article
  23. Li J, Pan P, Song W, Huang R, Chen K, Shang H: A meta-analysis of diffusion tensor imaging studies in amyotrophic lateral sclerosis. Neurobiol.Aging. 2011, 33 (8): 1833-1888.PubMedView Article
  24. Ellis CM, Suckling J, Amaro E, Bullmore ET, Simmons A, Williams SC, et al: Volumetric analysis reveals corticospinal tract degeneration and extramotor involvement in ALS. Neurology. 2001, 57: 1571-1578. 10.1212/WNL.57.9.1571.PubMedView Article
  25. Chang JL, Lomen-Hoerth C, Murphy J, Henry RG, Kramer JH, Miller BL, et al: A voxel-based morphometry study of patterns of brain atrophy in ALS and ALS/FTLD. Neurology. 2005, 65: 75-80. 10.1212/01.wnl.0000167602.38643.29.PubMedView Article
  26. Kassubek J, Unrath A, Huppertz HJ, Lule D, Ethofer T, Sperfeld AD, et al: Global brain atrophy and corticospinal tract alterations in ALS, as investigated by voxel-based morphometry of 3-D MRI. Amyotroph Lateral Scler Other Motor Neuron Disord. 2005, 6: 213-220. 10.1080/14660820510038538.PubMedView Article
  27. Ciccarelli O, Behrens TE, Johansen-Berg H, Talbot K, Orrell RW, Howard RS, et al: Investigation of white matter pathology in ALS and PLS using tract-based spatial statistics. Hum Brain Mapp. 2009, 30: 615-624. 10.1002/hbm.20527.PubMedView Article
  28. Filippini N, Douaud G, Mackay CE, Knight S, Talbot K, Turner MR: Corpus callosum involvement is a consistent feature of amyotrophic lateral sclerosis. Neurology. 2010, 75: 1645-1652. 10.1212/WNL.0b013e3181fb84d1.PubMed CentralPubMedView Article
  29. Abrahams S, Leigh PN, Goldstein LH: Cognitive change in ALS: a prospective study. Neurology. 2005, 64: 1222-1226. 10.1212/01.WNL.0000156519.41681.27.PubMedView Article
  30. Raaphorst J, de Visser M, van Tol MJ, Linssen WH, van der Kooi AJ, de Haan RJ, et al: Cognitive dysfunction in lower motor neuron disease: executive and memory deficits in progressive muscular atrophy. J Neurol Neurosurg Psychiatry. 2011, 82: 170-175. 10.1136/jnnp.2009.204446.PubMedView Article
  31. Swash M, Scholtz CL, Vowles G, Ingram DA: Selective and asymmetric vulnerability of corticospinal and spinocerebellar tracts in motor neuron disease. J Neurol Neurosurg Psychiatry. 1988, 51: 785-789. 10.1136/jnnp.51.6.785.PubMed CentralPubMedView Article
  32. Takahashi H, Oyanagi K, Ikuta F, Tanaka M, Yuasa T, Miyatake T: Widespread multiple system degeneration in a patient with familial amyotrophic lateral sclerosis. J Neurol Sci. 1993, 120: 15-21. 10.1016/0022-510X(93)90018-T.PubMedView Article
  33. Konrad C, Henningsen H, Bremer J, Mock B, Deppe M, Buchinger C, et al: Pattern of cortical reorganization in amyotrophic lateral sclerosis: a functional magnetic resonance imaging study. Exp Brain Res. 2002, 143: 51-56. 10.1007/s00221-001-0981-9.PubMedView Article
  34. Konrad C, Jansen A, Henningsen H, Sommer J, Turski PA, Brooks BR, et al: Subcortical reorganization in amyotrophic lateral sclerosis. Exp Brain Res. 2006, 172: 361-369. 10.1007/s00221-006-0352-7.PubMedView Article
  35. Schoenfeld MA, Tempelmann C, Gaul C, Kuhnel GR, Duzel E, Hopf JM, et al: Functional motor compensation in amyotrophic lateral sclerosis. J Neurol. 2005, 252: 944-952. 10.1007/s00415-005-0787-y.PubMedView Article
  36. Han J, Ma L: Functional magnetic resonance imaging study of the brain in patients with amyotrophic lateral sclerosis. Chin Med Sci J. 2006, 21: 228-233.PubMed
  37. Agosta F, Valsasina P, Absinta M, Riva N, Sala S, Prelle A, et al: Sensorimotor functional connectivity changes in amyotrophic lateral sclerosis. Cereb Cortex. 2011, 21: 2291-2298. 10.1093/cercor/bhr002.PubMedView Article
  38. Thivard L, Pradat PF, Lehericy S, Lacomblez L, Dormont D, Chiras J, et al: Diffusion tensor imaging and voxel based morphometry study in amyotrophic lateral sclerosis: relationships with motor disability. J Neurol Neurosurg Psychiatry. 2007, 78: 889-892. 10.1136/jnnp.2006.101758.PubMed CentralPubMedView Article
  39. Penhune VB, Doyon J: Cerebellum and M1 interaction during early learning of timed motor sequences. Neuroimage. 2005, 26: 801-812. 10.1016/j.neuroimage.2005.02.041.PubMedView Article
  40. Jacob S, Finsterbusch J, Weishaupt JH, Khorram-Sefat D, Frahm J, Ehrenreich H: Diffusion tensor imaging for long-term follow-up of corticospinal tract degeneration in amyotrophic lateral sclerosis. Neuroradiology. 2003, 45: 598-600. 10.1007/s00234-003-1014-0.PubMedView Article
  41. Nickerson JP, Koski CJ, Boyer AC, Burbank HN, Tandan R, Filippi CG: Linear longitudinal decline in fractional anisotropy in patients with amyotrophic lateral sclerosis: preliminary results. Klin Neuroradiol. 2009, 19: 129-134. 10.1007/s00062-009-8040-1.PubMedView Article
  42. Zhang Y, Schuff N, Woolley SC, Chiang GC, Boreta L, Laxamana J, et al: Progression of white matter degeneration in amyotrophic lateral sclerosis: A diffusion tensor imaging study. Amyotroph Lateral Scler. 2011, 12: 421-429. 10.3109/17482968.2011.593036.PubMed CentralPubMedView Article
  43. Senda J, Kato S, Kaga T, Ito M, Atsuta N, Nakamura T, et al: Progressive and widespread brain damage in ALS: MRI voxel-based morphometry and diffusion tensor imaging study. Amyotroph Lateral Scler. 2011, 12: 59-69. 10.3109/17482968.2010.517850.PubMedView Article
  44. Turner MR, Grosskreutz J, Kassubek J, Abrahams S, Agosta F, Benatar M, et al: Towards a neuroimaging biomarker for amyotrophic lateral sclerosis. Lancet Neurol. 2011, 10: 400-403. 10.1016/S1474-4422(11)70049-7.PubMedView Article

Copyright

© Keil et al.; licensee BioMed Central Ltd. 2012

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement